Companies · Biotechnology

X-Base BN Development, L.L.C.

GEORGETOWN · Biotechnology

Diligence memoA one-page analyst read on X-Base BN Development, L.L.C. — recommendation, valuation, rhythm, risks.→
$1.5M
Total raised · real
1
Rounds
—
Latest step-up
Top 77%
Sector rank · raised
Seed
Latest stage · inferred · Mon Nov 22 2021 00:00:00 GMT+0000 (Coordinated Universal Time)

X-Base BN Development, L.L.C. looks under-valued against its niche peers and is dormant on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the biotech sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Under-valued
  • Modeled value is 0.48× the median modeled value of Seed Biotechnology companies in 2019–2021 (186 peers) — value vs value, same stage and era.
Dormant
  • Last raise 4.6 yr ago; this sector typically re-raises about every 14 months.
  • Only one round on record and long silent — often defunct, acquired, or gone quiet.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Biotechnology

X-Base BN Development, L.L.C. is one of 4293 Biotechnology companies tracked from GEORGETOWN. By capital raised it ranks in the long tail (ahead of 24% of sector peers), and in the long tail by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Rule 506(b)
Reg D exemption
17
Investors (latest)
2021
Year incorporated
2021-11-22
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$13M$25M$38M$50MSeed · 2021-11-22 Raised $1.5M (real) Modeled valuation $31M (est)$1.5M$31MSeed2021

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Seed$1.5M · 2021

Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 50%.

Modeled valuation trajectory
$30.8M
Base estimate est.
$1.1M
Conservative case
$165.9M
Upside case
$7.5M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Seed — a $1.0M–$4.0M round). Valuation is modeled from stage benchmarks scaled by the biotech sector profile. Directional, not a quoted figure.

Not enough modeled valuation points to chart a trajectory.

Model inputs · modeled:benchmark-stage-stepup-v1
20%
Dilution assumption
Implied ownership sold in the financing.
32%
Survival probability
14% low · 50% high
1.74×/yr
Annual markup
2.28×/yr upside case
4.6 yr
Elapsed time used
4.6 yr actual, capped for stale marks
biotech
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
—
Avg between rounds
—
Capital velocity
4.9 yr
On record since
2021
First round
1
Rounds on file
How it compares to the market

Benchmarked against 4293 companies in Biotechnology. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages)▼ 0.2× of median
This company$1.5M
Sector median$7.2M
Latest round — vs other Seed rounds in sector (real $, this stage)▼ 0.9× of median
This company$1.5M
Sector median$1.7M
Modeled value — vs sector median (estimate, all stages)▼ 0.5× of median
This company$30.8M
Sector median$64.2M

Raised more than 24% of sector peers (real $). Modeled value above 36% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Seed) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #152 of 186.

This companyCohort peer
$10.0M$100.0M$1.0B$1.0M$10.0MCapital raised (log)Novo Biosciences, Inc. · Seed Raised $4.0M · modeled $177.6M (est)Entac Medical, Inc. · Seed Raised $4.0M · modeled $177.6M (est)ReGelTec, Inc. · Seed Raised $6.0M · modeled $177.6M (est)Korro Bio, Inc. · Seed Raised $4.0M · modeled $177.6M (est)TamuroBio Inc. · Seed Raised $4.0M · modeled $177.6M (est)Initial Therapeutics, Inc. · Seed Raised $3.8M · modeled $168.6M (est)Helaina Inc · Seed Raised $4.4M · modeled $165.0M (est)Onchilles Pharma, Inc. · Seed Raised $3.6M · modeled $158.5M (est)UVision 360, Inc. · Seed Raised $4.6M · modeled $155.7M (est)Safeguard Biosystems Holdings Ltd · Seed Raised $3.5M · modeled $155.4M (est)Enable Medicine Inc. · Seed Raised $3.6M · modeled $152.3M (est)Newomics Inc. · Seed Raised $3.9M · modeled $149.0M (est)X-Base BN Development, L.L.C. (this company) Raised $1.5M · modeled $30.8M (est)X-Base BN Development, L.L.C.
CompanyStageRaised · realValue · estvs peer med.
Novo Biosciences, Inc.Seed$4.0M$177.6M2.76×
Entac Medical, Inc.Seed$4.0M$177.6M2.76×
ReGelTec, Inc.Seed$6.0M$177.6M2.76×
Korro Bio, Inc.Seed$4.0M$177.6M2.76×
TamuroBio Inc.Seed$4.0M$177.6M2.76×
Initial Therapeutics, Inc.Seed$3.8M$168.6M2.62×
Helaina IncSeed$4.4M$165.0M2.57×
Onchilles Pharma, Inc.Seed$3.6M$158.5M2.47×
UVision 360, Inc.Seed$4.6M$155.7M2.42×
Safeguard Biosystems Holdings LtdSeed$3.5M$155.4M2.42×
Enable Medicine Inc.Seed$3.6M$152.3M2.37×
Newomics Inc.Seed$3.9M$149.0M2.32×
X-Base BN Development, L.L.C. this companySeed$1.5M$30.8M0.48×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Seed$1.5M2021-11-22$7.5M$30.8M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Seed$1.5M2021-11-22
    • First recorded raise — entered as Seed.
    • 17 investors on this round.
Intelligence
—
Modeled next raise
$2.4M
Modeled next size est.range $1.6M–$3.8M
—
Last step-up
—
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Don W. Berry—1 other2021-11
Registry & provenance

X-Base BN Development, L.L.C. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1906334
SEC CIK
2021
Incorporated
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
X-Rase RD Development, LLCBiotechnologySeed$1.5M$41.4Mnetwork1 shared operator · same sector · same stage
Rasio Therapeutics, Inc.BiotechnologySeed$1.5M$31.3Msame sector · same stage
LumeNXT LLCBiotechnologySeed$1.5M$30.9Msame sector · same stage
Enkefalos Biosciences, Inc.BiotechnologySeed$1.5M$34.8Msame sector · same stage
Vitranu, Inc.BiotechnologySeed$1.5M$33.0Msame sector · same stage
BioHybrid Solutions Holdings, Inc.BiotechnologySeed$1.5M$25.6Msame sector · same stage
Qualia Oto, Inc.BiotechnologySeed$1.4M$27.5Msame sector · same stage
Cognigenics, Inc.BiotechnologySeed$1.6M$24.0Msame sector · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
X-Biomedical Inc.BiotechnologyPre-Seed$23.5M86%
X-Rase RD Development, LLCBiotechnologySeed$41.4M85%
Xcell Biosciences, Inc.BiotechnologySeries B$8.3M85%
Xeno Biosciences Inc.BiotechnologySeries A$16.4M84%
Xenetic Biosciences, Inc.BiotechnologySeries A$5.9M84%
SciTech Development L.L.C.BiotechnologySeed$1.0M83%
X-Vax Technology, Inc.BiotechnologySeries C$2.3B83%
X-Therma Inc.BiotechnologySeries B$182.8M83%
Frequently asked
How much funding has X-Base BN Development, L.L.C. raised?
X-Base BN Development, L.L.C. has raised approximately $1.5M in disclosed capital across 1 recorded financing round, aggregated from public filings.
What is X-Base BN Development, L.L.C.'s estimated valuation?
Provath's modeled valuation for X-Base BN Development, L.L.C. is approximately $30.8M (modeled range $1.1M–$165.9M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is X-Base BN Development, L.L.C. at?
X-Base BN Development, L.L.C.'s latest modeled financing stage is Seed. Its most recent recorded round closed around Mon Nov 22.
What does X-Base BN Development, L.L.C. do and where is it based?
X-Base BN Development, L.L.C. operates in the Biotechnology sector, based in GEORGETOWN.
Explore related

See where X-Base BN Development, L.L.C. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at X-Base BN Development, L.L.C., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.